Showing 464 results
-
Media Release /- Latest Phase III research on Afinitor® in advanced HER2 positive breast cancer- Jakavi™ overall survival advantage evaluated in three-year study in patients with myelofibrosis, a rare and life-…
-
Media Release /- 104 Week sub-analysis data from the Cosentyx Phase III FUTURE 1 trial in patients with psoriatic arthritis (PsA) presented at ACR 2015(1,2)- Patients receiving Cosentyx through 104 weeks maintained…
-
Media Release /-- In the FUTURE 1 study, secukinumab met the primary endpoint showing statistically significant efficacy versus placebo in improving signs and symptoms of active psoriatic arthritis (PsA)-- All pre-…
-
Media Release /- New data at AAD shows 7 out of 10 psoriasis patients who were PASI 75 responders at 52 weeks achieved clear to almost clear skin (PASI 90) after two years of Cosentyx 300 mg treatment- After two…
-
Media Release /Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of…
-
Media Release /FDA approval for Cosentyx is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis…
-
Media Release /Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients1-5 In APPLY-PNH…
-
Media Release /- BYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase inhibitor or after…
-
Media Release /- TOBI Podhaler is portable and requires no nebulizer, refrigeration or power source to deliver the medicine- TOBI Podhaler is indicated for certain cystic fibrosis (CF) patients with Pa and shortens…
-
Media Release /- Mayzent® (siponimod) is the first and only oral treatment specifically indicated for active secondary progressive multiple sclerosis (SPMS) in adults- Up to 80% of patients with relapsing remitting…
